Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline with BCD in Newly Diagnosed AL Amyloidosis
NCT03401372Completed
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of doxycycline in Amyloid Light Chain Amyloidosis (2 arms). Primary endpoint: Progression-free survival at 2 years. Started Apr 2018; status: completed.
02
Drugs
doxycycline
03
Conditions
Amyloid Light Chain Amyloidosis
Beyond the preview
Go deeper on NCT03401372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03401372.